WO1999056666A8 - The treatment of sexual dysfunction in certain patient groups - Google Patents

The treatment of sexual dysfunction in certain patient groups

Info

Publication number
WO1999056666A8
WO1999056666A8 PCT/US1999/009610 US9909610W WO9956666A8 WO 1999056666 A8 WO1999056666 A8 WO 1999056666A8 US 9909610 W US9909610 W US 9909610W WO 9956666 A8 WO9956666 A8 WO 9956666A8
Authority
WO
WIPO (PCT)
Prior art keywords
sexual dysfunction
patient groups
treatment
certain patient
methods
Prior art date
Application number
PCT/US1999/009610
Other languages
French (fr)
Other versions
WO1999056666A1 (en
Original Assignee
Rt Alamo Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/071,457 external-priority patent/US6110489A/en
Priority claimed from US09/166,703 external-priority patent/US6194433B1/en
Priority claimed from US09/175,395 external-priority patent/US6132753A/en
Priority claimed from US09/260,099 external-priority patent/US6132757A/en
Priority claimed from US09/262,715 external-priority patent/US6187790B1/en
Priority to AU37806/99A priority Critical patent/AU3780699A/en
Priority to BR9908716-2A priority patent/BR9908716A/en
Priority to MXPA00010254A priority patent/MXPA00010254A/en
Priority to JP2000599185A priority patent/JP2002537231A/en
Application filed by Rt Alamo Ventures Inc filed Critical Rt Alamo Ventures Inc
Priority to EP99920266A priority patent/EP1079764A4/en
Priority to CA002319542A priority patent/CA2319542C/en
Publication of WO1999056666A1 publication Critical patent/WO1999056666A1/en
Publication of WO1999056666A8 publication Critical patent/WO1999056666A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Methods for treating specific patient groups for sexual dysfunction are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions in patients who are free of cardiac disease and/or who have not been given organic nitrates.
PCT/US1999/009610 1998-05-01 1999-04-30 The treatment of sexual dysfunction in certain patient groups WO1999056666A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002319542A CA2319542C (en) 1998-05-01 1999-04-30 The treatment of sexual dysfunction in certain patient groups
EP99920266A EP1079764A4 (en) 1998-05-01 1999-04-30 The treatment of sexual dysfunction in certain patient groups
AU37806/99A AU3780699A (en) 1998-05-01 1999-04-30 The treatment of sexual dysfunction in certain patient groups
JP2000599185A JP2002537231A (en) 1998-05-01 1999-04-30 Treatment of sexual dysfunction in specific patient groups
MXPA00010254A MXPA00010254A (en) 1998-05-01 1999-04-30 The treatment of sexual dysfunction in certain patient groups.
BR9908716-2A BR9908716A (en) 1998-05-01 1999-04-30 Treatment of sexual dysfunction in certain groups of patients

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US09/071,457 1998-05-01
US09/071,457 US6110489A (en) 1998-05-01 1998-05-01 Use of quinolines and quinolones to treat male erectile dysfunction
US09/166,703 1998-10-05
US09/166,703 US6194433B1 (en) 1998-10-05 1998-10-05 Sexual dysfunction in females
US09/175,395 US6132753A (en) 1998-05-01 1998-10-19 Treatment of sexual dysfunction in certain patient groups
US09/175,395 1998-10-19
US09/260,099 US6132757A (en) 1998-05-01 1999-03-02 Treatment of sexual dysfunction in certain patient groups
US09/260,099 1999-03-02
US09/262,715 US6187790B1 (en) 1999-03-04 1999-03-04 Use of cilostazol for treatment of sexual dysfunction
US09/262,715 1999-03-04

Publications (2)

Publication Number Publication Date
WO1999056666A1 WO1999056666A1 (en) 1999-11-11
WO1999056666A8 true WO1999056666A8 (en) 2000-08-10

Family

ID=27535884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/009610 WO1999056666A1 (en) 1998-05-01 1999-04-30 The treatment of sexual dysfunction in certain patient groups

Country Status (7)

Country Link
EP (1) EP1079764A4 (en)
JP (1) JP2002537231A (en)
AU (1) AU3780699A (en)
BR (1) BR9908716A (en)
CA (1) CA2319542C (en)
MX (1) MXPA00010254A (en)
WO (1) WO1999056666A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6541487B1 (en) * 1998-05-01 2003-04-01 R.T. Alamo Ventures I, Llc PDE III inhibitors for treating sexual dysfunction
WO2002058703A2 (en) * 2001-01-26 2002-08-01 R.T. Alamo Ventures I, Llc The treatment of sexual dysfunction and cardiovascular disease with quinolinone enantiomers
US6727262B2 (en) 2002-03-01 2004-04-27 R.T. Alamo Ventures I, Llc Dichlorinated heterocyclic compounds and methods of synthesis
US6767914B2 (en) 2002-03-01 2004-07-27 R.T. Alamo Ventures I, Llc Fluorinated heterocyclic compounds and methods of synthesis
US6730790B2 (en) 2002-03-01 2004-05-04 R.T. Alamo Ventures I. Llc Chlorinated heterocyclic compounds and methods of synthesis
US7041677B2 (en) 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
GB0208704D0 (en) * 2002-04-16 2002-05-29 Futura Medical Dev Ltd Condom
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
TWI338583B (en) 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
DE4117249C2 (en) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomine used to treat erectile dysfunction
EP0651640A1 (en) * 1992-07-21 1995-05-10 Knoll AG Use of 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone in the treatment of angina pectoris
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
WO2000007595A1 (en) * 1998-08-03 2000-02-17 Basf Corporation Pyridinones for the treatment of sexual dysfunction

Also Published As

Publication number Publication date
EP1079764A1 (en) 2001-03-07
BR9908716A (en) 2000-11-21
JP2002537231A (en) 2002-11-05
CA2319542A1 (en) 1999-11-11
MXPA00010254A (en) 2002-08-06
WO1999056666A1 (en) 1999-11-11
AU3780699A (en) 1999-11-23
EP1079764A4 (en) 2001-09-12
CA2319542C (en) 2005-07-12

Similar Documents

Publication Publication Date Title
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2004019884A3 (en) Agents and methods for enhancing bone formation
WO2005027842A3 (en) Combinations of drugs for the treatment of neoplasms
WO2002041837A3 (en) Treatment of mucositis
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
BR9813318A (en) Process of treating tumors and macular degeneration in a human or veterinary patient, pharmaceutical composition for treating tumors and macular degeneration in a human or veterinary patient
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
PT1237562E (en) PROCESS OF PREPARATION OF MYCANYAN EXTRACTS CONTAINING MICANOLIDE AND DIHYDROMICANOLID AND USES IN THE TREATMENT OF PROLIFERATIVE DISEASES
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
EP0744176A3 (en) Methods for inhibiting bone loss
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
MA26648A1 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF BONE DISEASES, AND METHOD FOR THEIR PREPARATION.
WO2000078800A3 (en) Combined decorin binding protein and outer surface protein compositions and methods of use
DE69733321D1 (en) OLANZAPINE FOR THE TREATMENT OF DRUG ABUSE
UA32241A (en) Method for treating inflammations in experiment
AU2002300509A1 (en) The Treatment of Sexual Dysfunction in Certain Patient Groups
EA200001091A1 (en) METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF SPECIFICATIONS
UA36490A (en) Method for treating pyo-septical diseases of soft tissues
UA34303A (en) Method for treating myocarditis
UA28928A (en) Method of purulent-inflammatory desease of soft tissues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 37806/99

Country of ref document: AU

Ref document number: 1999920266

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2319542

Country of ref document: CA

Ref document number: 2319542

Country of ref document: CA

Kind code of ref document: A

AK Designated states

Kind code of ref document: C1

Designated state(s): AU BR CA JP MX

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 45/99 UNDER (81) ADD "BR, JP, MX"; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase in:

Ref document number: 2000 599185

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/A/2000/010254

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1999920266

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999920266

Country of ref document: EP